|
|
Article: CSL Marks 40 Years in the Influenza Vaccine Market.
- Article from:
- Business Wire
- Article date:
- May 13, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
A Leading Provider of Vaccine in the Southern Hemisphere and Europe
PARKVILLE, Australia -- CSL Limited today celebrated its 40th year as a leading manufacturer of the influenza (flu) vaccine. The company's vaccine, Fluvax([R]), is a Thiomersal-free influenza vaccine that is approved for use in adults and children in Australia and New Zealand. This vaccine is known as Afluria[TM], Enzira[TM], Nilgrip[TM], and X-Flu[TM] in 17 different countries, including the US and European markets. Additionally, CSL supplies the antigen used to manufacture the flu vaccine in 24 countries.
CSL's prominence in the influenza vaccine market has grown dramatically over the ...
Related newspaper, magazine, and journal articles:
|
|
Article: CSL Biotherapies Contracts with U.S. Department of ...
Business Wire;
May 29, 2009 ;
700+ words
... ... difference." CSL Biotherapies' Novel A (H1N1 ... influenza strain. CSL Limited, parent company to CSL Biotherapies, is currently ... headquarters of CSL Biotherapies are located in ... parent company, CSL Limited, in Melbourne ...
|
|